FDA — authorised 30 April 1987
- Marketing authorisation holder: MERCK SHARP DOHME
- Status: approved
🇺🇸 Elocon in United States
FDA authorised Elocon on 30 April 1987
Marketing authorisations
FDA — authorised 30 April 1987
- Application: NDA019543
- Marketing authorisation holder: ORGANON
- Local brand name: ELOCON
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 6 May 1987
- Application: NDA019625
- Marketing authorisation holder: ORGANON
- Local brand name: ELOCON
- Indication: CREAM — TOPICAL
- Status: approved
FDA — authorised 30 March 1989
- Application: NDA019796
- Marketing authorisation holder: ORGANON
- Local brand name: ELOCON
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 18 March 2002
- Application: ANDA076067
- Marketing authorisation holder: PADAGIS US
- Local brand name: MOMETASONE FUROATE
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 14 November 2003
- Application: ANDA076481
- Marketing authorisation holder: ENCUBE
- Local brand name: MOMETASONE FUROATE
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 3 December 2004
- Application: ANDA076624
- Marketing authorisation holder: SUN PHARMA CANADA
- Local brand name: MOMETASONE FUROATE
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 21 December 2004
- Application: ANDA076679
- Marketing authorisation holder: SUN PHARMA CANADA
- Local brand name: MOMETASONE FUROATE
- Indication: CREAM — TOPICAL
- Status: approved
FDA — authorised 28 March 2005
- Application: ANDA077061
- Marketing authorisation holder: FOUGERA PHARMS
- Local brand name: MOMETASONE FUROATE
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 6 April 2005
- Application: ANDA077180
- Marketing authorisation holder: PADAGIS ISRAEL
- Local brand name: MOMETASONE FUROATE
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 8 April 2005
- Application: ANDA076171
- Marketing authorisation holder: FOUGERA PHARMS
- Local brand name: MOMETASONE FUROATE
- Indication: CREAM — TOPICAL
- Status: approved
FDA — authorised 15 March 2006
- Application: ANDA076788
- Marketing authorisation holder: SUN PHARMA CANADA
- Local brand name: MOMETASONE FUROATE
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 22 May 2006
- Application: ANDA077447
- Marketing authorisation holder: COSETTE
- Local brand name: MOMETASONE FUROATE
- Indication: CREAM — TOPICAL
- Status: approved
FDA — authorised 20 June 2006
- Application: ANDA077401
- Marketing authorisation holder: COSETTE
- Local brand name: MOMETASONE FUROATE
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 18 April 2007
- Application: ANDA076591
- Marketing authorisation holder: CHARTWELL MOLECULAR
- Local brand name: MOMETASONE FUROATE
- Indication: CREAM — TOPICAL
- Status: approved
FDA — authorised 21 November 2007
- Application: ANDA077678
- Marketing authorisation holder: COSETTE
- Local brand name: MOMETASONE FUROATE
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 21 November 2007
- Application: ANDA076499
- Marketing authorisation holder: ENCUBE
- Local brand name: MOMETASONE FUROATE
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 29 November 2007
- Application: ANDA075919
- Marketing authorisation holder: FOUGERA PHARMS
- Local brand name: MOMETASONE FUROATE
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 28 May 2008
- Application: ANDA078541
- Marketing authorisation holder: GLENMARK PHARMS
- Local brand name: MOMETASONE FUROATE
- Indication: CREAM — TOPICAL
- Status: approved
FDA — authorised 28 May 2008
- Application: ANDA078571
- Marketing authorisation holder: GLENMARK PHARMS
- Local brand name: MOMETASONE FUROATE
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 9 August 2010
- Application: ANDA090506
- Marketing authorisation holder: GLENMARK PHARMS LTD
- Local brand name: MOMETASONE FUROATE
- Indication: LOTION — TOPICAL
- Status: approved
FDA — authorised 22 March 2016
- Application: ANDA091161
- Marketing authorisation holder: APOTEX
- Local brand name: MOMETASONE FUROATE
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 3 April 2017
- Application: ANDA207989
- Marketing authorisation holder: AMNEAL PHARMS
- Local brand name: MOMETASONE FUROATE
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 8 December 2017
- Application: NDA209310
- Marketing authorisation holder: INTERSECT ENT INC
- Local brand name: SINUVA
- Indication: IMPLANT — IMPLANTATION
- Status: approved
FDA — authorised 13 July 2018
- Application: ANDA207899
- Marketing authorisation holder: TORRENT
- Local brand name: MOMETASONE FUROATE
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 13 January 2022
- Application: NDA211746
- Marketing authorisation holder: GLENMARK SPECLT
- Local brand name: RYALTRIS
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 17 March 2022
- Application: NDA215712
- Marketing authorisation holder: PERRIGO PHARMA INTL
- Local brand name: NASONEX 24HR ALLERGY
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 14 June 2023
- Application: ANDA217460
- Marketing authorisation holder: AMNEAL
- Local brand name: MOMETASONE FUROATE
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 18 March 2024
- Application: ANDA215878
- Marketing authorisation holder: AUROBINDO PHARMA
- Local brand name: MOMETASONE FUROATE
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 23 April 2024
- Application: ANDA217438
- Marketing authorisation holder: APOTEX
- Local brand name: MOMETASONE FUROATE
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 22 November 2024
- Application: ANDA217498
- Marketing authorisation holder: AUROBINDO PHARMA
- Local brand name: MOMETASONE FUROATE
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 15 May 2025
- Application: ANDA211706
- Marketing authorisation holder: NASPRESS
- Local brand name: MOMETASONE FUROATE
- Indication: SPRAY, METERED — NASAL
- Status: approved
Elocon in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Elocon approved in United States?
Yes. FDA authorised it on 30 April 1987; FDA authorised it on 30 April 1987; FDA authorised it on 6 May 1987.
Who is the marketing authorisation holder for Elocon in United States?
MERCK SHARP DOHME holds the US marketing authorisation.